ADC Therapeutics SA ADCT
ADC Therapeutics SA (NYSE: ADCT) is an oncology drug developer. Its lead program, ZYNLONTA (loncastuximab tesirine-lpyl), is in Phase 3 for relapsed/refractory DLBCL after two or more lines of systemic therapy. Its next catalyst on record is ZYNLONTA (MZL IIT): Presentation of updated MZL data (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ZYNLONTA (MZL IIT) — Presentation of updated MZL data (2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ZYNLONTA monotherapy (3L+ DLBCL) | r/r DLBCL, 3L+ | antibody | Approved |
| ZYNLONTA + rituximab (LOTIS-5) | r/r DLBCL, 2L+ | antibody | Phase 3 |
| ZYNLONTA + rituximab (IIT) | r/r follicular lymphoma | antibody | Phase 2 |
| ZYNLONTA monotherapy (IIT) | marginal zone lymphoma | antibody | Phase 2 |
| ZYNLONTA + glofitamab (LOTIS-7) | r/r DLBCL | antibody | Phase 1 |
| ADCT-241 (PSMA-targeting exatecan ADC) | prostate cancer (PSMA) | antibody | Pre-clinical |
Recent results and decisions
- Nov 4, 2026met LOTIS-5 Phase 3 trial met primary endpoint of PFS with statistical significance (HR=0.73, p=0.0083) in r/r DLBCL, but FDA raised serious concerns regarding benefit-risk due to Grade 5 safety imbalance.
Study met primary PFS endpoint with statistical significance (HR=0.73, two-sided p-value 0.008) and resulted in a higher CR rate with ZYNLONTA + rituximab vs. R-GemOx (~40% vs ~27%).
Filing - Nov 4, 2026submitted Tanabe Pharma filed marketing authorization application with Japan's Ministry of Health for ZYNLONTA and entered into exclusive sublicensing agreement with Nippon Shinyaku.
Tanabe Pharma filed for Japanese approval of ZYNLONTA and entered into exclusive sublicensing agreement with Nippon Shinyaku.
Filing - Jun 3, 2026met LOTIS-5 met primary PFS endpoint (HR 0.73, p=0.008; median 6.1 vs 4.7 months) but with more serious AEs (49.0% vs 34.5%) and Grade 5 TEAEs (13.2% vs 4.6%) in the ZYNLONTA arm; OS HR 0.96.
The study met the primary endpoint of progression-free survival (“PFS”) (per independent review committee) with statistical significance (HR = 0.73; p-value = 0.008 two sided), with a median PFS of 6.1 months for ZYNLONTA plus rituximab vs 4.7 months for R-GemOx.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.